5 Booming Biotech And Health Care Stocks to Buy Now

Its recession-proof, its vital to our very survival and its not going away any
time soon. The biotechnology and health care industries are growing at
incredible rates, and some of the top companies in this sector are seeing
returns of well over 70% over the past year. With the health care industry
expected to grow by an average of 5.8% per year through 2020 , investors would
be foolish to miss out on sch gargantuan opportunities. I watch more than 5,000
publicly traded companies with my Portfolio Grader tool, ranking companies by a
number of fundamental and quantitative measures. And this week, five biotech and
healthcare stocks to buy. Here they are, in alphabetical order. Each one of
these stocks gets an "A" or "B" according to my research, meaning it is
a "strong buy" or "buy." Alexion Pharmaceuticals (NASDAQ: ALXN )
discovers, develops and commercializes therapeutic products for life-threatening
diseases. ALXN has posted a significant gain of 75% in the last year. ALXN stock
gets an "A" for sales growth, an "A" for earnings growth, an "A" for
earnings momentum, an "A" for its ability to exceed the consensus earnings
estimates on Wall Street and a "B" for return on equity in my Portfolio
Grader tool. For more information, view my complete analysis of ALXN stock .
Amgen (NASDAQ: AMGN ) is involved with medication for grievous illnesses. In the
last year, AMGN stock is up 29%, compared to just 5% for the Dow. AMGN stock
gets a "B" for its ability to exceed the consensus earnings estimates on
Wall Street, a "B" for the magnitude in which earnings projections have
increased over the past month, a "B" for cash flow and a "B" for return
on equity in my Portfolio Grader tool. For more information, view my complete
analysis of AMGN stock . Celgene (NASDAQ: CELG ) develops products for
hematology, oncology and immune-inflammatory diseases. CELG is up almost 30% in
the last 12 months. CELG stock gets an "A" for sales growth, a "B" for
earnings growth, an "A" for earnings momentum, a "B" for the magnitude
in which earnings projections have increased over the past month, a "B" for
cash flow and an "A" for return on equity in my Portfolio Grader tool. For
more information, view my complete analysis of CELG stock . Regeneron
Pharmaceuticals (NASDAQ: REGN ) is best known for its product ARCALYST, which is
used to treat Cryopyrin-Associated Periodic Syndromes (CAPS), which includes
Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).
REGN is the biggest winner on this list, posting a gain of nearly 140% in the
last year. REGN gets